Search results
Showing 76 to 90 of 138 results for sclerosis
than oral methylprednisolone in people with relapsing–remitting Multiple Sclerosis (MS) and people with secondary progressive MS with...
TA254/2 Question NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts, which uses...
Discontinued Reference number: GID-TA11476
This quality standard covers health and social care services for adults, young people and children with autism. It includes assessment and diagnosis of autism spectrum disorders, and care and support for people diagnosed with an autism spectrum disorder. It describes high-quality care in priority areas for improvement.
View quality statements for QS51Show all sections
Sections for QS51
- Quality statements
- Quality statement 1: Diagnostic assessment by an autism team
- Quality statement 2: Assessment and diagnosis
- Quality statement 3: Personalised plan
- Quality statement 4: Coordination of care and support
- Quality statement 5: Treating the core features of autism: psychosocial interventions
- Quality statement 6: Treating the core features of autism: medication
- Quality statement 7: Assessing possible triggers for behaviour that challenges
NICE has developed a medtech innovation briefing (MIB) on the Quantitative Timed Up and Go (QTUG)
product in UK: Sativex) for treating spasticity in people with multiple sclerosis. There were reductions in some measures of...
In development Reference number: GID-TA11310 Expected publication date: TBC
Percutaneous posterior tibial nerve stimulation for overactive bladder syndrome (IPG362)
Evidence-based recommendations on percutaneous posterior tibial nerve stimulation for overactive bladder syndrome. This involves inserting a fine needle into a nerve just above the ankle and passing a mild electric current to the nerves that control bladder function.
View recommendations for IPG362Show all sections
Sections for IPG362
Discontinued Reference number: GID-TAG368
Evidence-based recommendations on injectable bulking agents for faecal incontinence. This involves injecting a material into the muscles around the anus to bulk the sides of the sphincter.
View recommendations for IPG210Show all sections
Sections for IPG210
dysfunction, as well as those with spinal cord injury, spina bifida and multiple sclerosis. Reports of its use in other conditions are...
Functional electrical stimulation for drop foot of central neurological origin (IPG278)
Evidence-based recommendations on functional electrical stimulation for drop foot of central neurological origin. This involves stimulating the peripheral nerves that supply the paralysed muscle using electrodes to restore muscular function.
View recommendations for IPG278Show all sections
Sections for IPG278
Biotin for treating primary and secondary progressive multiple sclerosis [ID919]
Discontinued Reference number: GID-TA10099